Development of a model for marburgvirus based on severe-combined immunodeficiency mice
Kelly L. Warfield(Tulane University), Sina Bavari(Epix Pharmaceuticals (United States)), Sean Vantongeren(United States Army Medical Research Institute of Infectious Diseases), Steven B. Bradfute(New Mexico Department of Health), Warren V. Kalina(Pfizer (United States)), Derron A. Alves(United States Army Medical Research Institute of Infectious Diseases), Gene G. Olinger(Health Affairs), Daniel K. Reed(United States Army Medical Research Institute of Infectious Diseases)
Cited by 65
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
|New England Journal of Medicine|2021|937